Chimera Bioengineering

The company's core business revolves around overcoming the primary obstacles in Chimeric Antigen Receptor T-cell (CAR-T) therapy, such as severe toxicity, limited effectiveness against solid tumors, and lack of persistence. Chimera Bioengineering addresses these challenges by engineering what it describes as the "software" of the immune system. Its proprietary GOLD Platform™ utilizes RNA-based gene regulatory systems to precisely control the behavior of engineered CAR-T cells. This technology allows the therapeutic cells to produce anti-cancer proteins, or "payloads," specifically when they encounter tumor cells, thus minimizing harm to healthy tissue and reducing systemic toxicity. The platform aims to enhance the therapy's ability to counteract the immunosuppressive tumor microenvironment, which is a major barrier to treatment success.

The business model is centered on the research and development of a pipeline of proprietary cell therapies, with the goal of bringing them to clinical trials and eventual commercialization. Chimera's lead product candidate, CBIO-007, is a CAR-T therapy designed for multiple solid tumor indications, including pancreatic, prostate, and breast cancers. The company generates capital through venture funding to advance its product pipeline. It has successfully raised significant funds through multiple rounds, with a total of at least $26 million raised by April 2022 from investors including Kairos Venture Investments, The Angel's Forum, Founders Fund, and the Asian Fund for Cancer Research (AFCR). In May 2024, it was reported that Chimera was acquired by Vaxanix. The company also pursues strategic collaborations, offering its technology platform to optimize partners' programs.